NCT05693727View on ClinicalTrials.gov

Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2027

Conditions
Pleural Effusion, Malignant
Interventions
DIAGNOSTIC_TEST

pleural markers

Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}

All Listed Sponsors
lead

Assiut University

OTHER

NCT05693727 - Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion | Biotech Hunter | Biotech Hunter